EGFR and non-small cell lung carcinoma: In conclusion, in the absence of known EGFR mutational status, intercalating and maintenance use of gefitinib improves the PFS and OS of NSCLC patients of the adenocarcinoma subtype, or never or former light smokers who have achieved SD with chemotherapy.